- Published on
KembaraXtra-Medicine: Abdominal Aortic Aneurysm
An abdominal aortic aneurysm (AAA) is a segmental, full-thickness dilation of the abdominal aorta that measures at least 50% larger than the normal vessel diameter. Because the average infrarenal aortic diameter in adults is about 2 cm, an aortic diameter of 3.0 cm or greater is commonly used as the threshold for defining an AAA. The relevant ICD-10-CM codes include I71.4 for abdominal aortic aneurysm without rupture and I71.3 for abdominal aortic aneurysm with rupture.
AAA is primarily a disease of older adults and occurs far more often in men than women, with men affected about four times as frequently. In the United States, roughly 13,000 deaths per year are attributed to AAA. Among men older than 60 years, the prevalence is estimated at about 1.2% to 3.3%, which is lower than older reports, likely reflecting reductions in smoking rates. Importantly, men with a subaneurysmal aorta (about 2.6-2.9 cm) have a meaningful risk of progression, with more than half developing an AAA (>3.0 cm) within 5 years, and a notable proportion eventually reaching larger sizes over longer follow-up.
Most AAAs develop in the infrarenal aorta and tend to enlarge progressively over time, with faster expansion as diameter increases. Aneurysm size is the strongest predictor of rupture, and because larger aneurysms grow more quickly, surveillance intervals shorten as size increases. Typical monitoring intervals include imaging every 3 years for AAAs 3.0–3.9 cm, every 12 months for 4.0–4.9 cm, and every 6 months for 5.0–5.4 cm. Rupture is often catastrophic, especially outside the hospital setting, where mortality is commonly 80–90%. Female sex, older age, and especially current smoking are associated with higher rupture risk, and rupture risk rises steeply as aneurysm diameter increases, particularly once the AAA exceeds 5.5 cm.
Screening is designed to detect AAAs before rupture. The USPSTF recommends one-time screening ultrasound for men aged 65–75 who have ever smoked and suggests selective screening for older men who never smoked but have risk factors such as a first-degree family history. Repeat screening after a negative scan is generally not considered beneficial, and men older than 75 are unlikely to benefit. Evidence is currently insufficient to clearly define the balance of benefits and harms of screening women aged 65–75 who have smoked or have a family history. The Society for Vascular Surgery recommends one-time ultrasound screening for men and women aged 65–75 with tobacco history, for men and women aged 65–75 with a first-degree relative with AAA, and for selected patients older than 75 who are otherwise in good health and have smoking history or a first-degree relative with AAA.
Most AAAs are asymptomatic and discovered incidentally on imaging. Physical examination may reveal a pulsatile abdominal mass, but exam sensitivity is only moderate and becomes less reliable with larger abdominal girth; importantly, palpation does not increase rupture risk. When symptoms occur, they may include abdominal, back, flank, or groin pain, or symptoms caused by compression of nearby structures such as early satiety, nausea, vomiting, venous thrombosis from venous compression, ureteral obstruction with hydronephrosis, or distal thromboembolization causing leg pain and discoloration. A ruptured AAA can present with the classic triad of abdominal/back pain, hypotension, and a pulsatile mass, though this full triad is seen in only about half of cases, and rupture rapidly progresses to hemorrhagic shock requiring emergent repair.
AAA formation is driven by degenerative and inflammatory processes within the aortic wall, including smooth muscle cell loss, thinning of the media, infiltration by inflammatory cells, and breakdown of extracellular matrix components such as elastin, leading to progressive dilation and risk of rupture. Age is a major nonmodifiable risk factor, with markedly increased risk after 65 years. Smoking is the strongest modifiable risk factor, strongly linked to aneurysm formation, enlargement, and rupture. Family history also increases risk and may reflect inherited connective tissue susceptibility. Other associated conditions include hyperlipidemia, obesity, peripheral arterial disease, cerebrovascular disease, coronary artery disease, hypertension, and the presence of aneurysms elsewhere. Healthier dietary patterns and regular moderate exercise are associated with lower AAA risk, and moderate exercise does not appear to increase expansion or rupture risk.
Diagnosis is most often made by imaging rather than labs. AAA should be considered in the differential for patients with abdominal, back, or flank pain—especially older adults and smokers—and in those with a pulsatile abdominal mass. Important alternative diagnoses include aortic dissection, ulcerated aortic plaque, renal colic, mesenteric ischemia, pancreatitis, diverticulitis, peptic ulcer disease, and biliary disease. Laboratory testing is not routinely needed, but inflammatory markers and blood cultures may be considered if an inflammatory or infected aneurysm is suspected.
Ultrasound is the preferred screening and surveillance tool because it is noninvasive, widely available, and highly accurate. CT is typically used for preoperative planning and is the imaging modality of choice for symptomatic AAA or suspected rupture because it better defines anatomy, involvement near renal arteries, and signs of wall instability or rupture. MRA may also be used and can be highly accurate. Traditional diagnostic angiography has largely been replaced by noninvasive imaging, though angiographic techniques remain relevant in procedural planning and intraoperative decision-making.
Management depends on aneurysm size, symptoms, and overall surgical risk. Smoking cessation is essential because it reduces AAA expansion and rupture risk, and patients should be offered structured cessation support. Blood pressure and lipid control should follow standard cardiovascular prevention guidance, though medications such as statins or beta blockers are not used solely to prevent AAA expansion. Definitive treatment is aneurysm repair, performed either as open surgical repair (OSR) or endovascular aneurysm repair (EVAR). EVAR is generally favored when anatomy is suitable because it reduces short-term morbidity, but it requires lifelong surveillance for complications such as endoleaks, graft migration, fractures, infection, and aneurysm sac enlargement. CTA is commonly used early in follow-up, with ultrasound increasingly used for ongoing surveillance to reduce radiation and contrast exposure.
Elective repair is generally recommended for infrarenal or juxtarenal AAAs at about 5.5 cm or larger, for AAAs growing more than 0.5 cm in 6 months, and for any AAA that is symptomatic, regardless of size. For women, repair may be considered at slightly smaller diameters (often around 5.0 cm) depending on guideline and risk context. Ruptured AAA requires emergent repair, and symptomatic AAA usually requires urgent intervention. For small asymptomatic AAAs, studies show no clear advantage to early repair compared with careful imaging surveillance.
Referral to vascular surgery is recommended at the time an AAA is diagnosed so that surveillance, risk reduction, and timing of repair can be individualized. At the same time, it is important to optimize comorbidities—particularly coronary artery disease, pulmonary disease, and renal dysfunction—because these conditions increase operative risk and influence whether EVAR or open repair is appropriate.
0 Comments
